Real World Evidence Solutions, QuintilesIMS, London, UK; Institute of Pharmaceutical Science, King's College, London.
Medical Evidence & Observational Research, Global Medical Affairs, AstraZeneca, Gaithersburg, USA.
Diabetes Res Clin Pract. 2017 Mar;125:29-38. doi: 10.1016/j.diabres.2016.10.025. Epub 2016 Nov 9.
Dapagliflozin is an inhibitor of the human sodium-glucose co-transporter 2 (SGLT2) that has been shown to improve glycaemic control in patients with type 2 diabetes mellitus (T2DM). This study aimed to evaluate the characteristics and treatment patterns of dapagliflozin users in comparison to users of other anti-diabetic (AD) treatments in Germany.
Data from patients with T2DM initiating at least one prescription for dapagliflozin or other AD therapy between November 2012 and April 2014 were collected from the IMS German Disease Analyzer database.
The use of dapagliflozin combination therapy (n=1034; 74%) was more common than monotherapy (n=371; 26%). In comparison with other AD therapy users, a higher percentage of dapagliflozin users were ⩽64years of age (62.3% vs. 36.4%), and a higher proportion were male (59.1% vs. 53.6%). The average duration of diabetes was comparable between dapagliflozin patients and other AD therapy users (5.7yearsvs. 5.5years), however higher levels of HbA1c were found in dapagliflozin users (8.2% (66mmol/mol) vs. 7.5% (58mmol/mol). For the vast majority (71.5% of 10mg dapagliflozin users and 88.9% of 5mg users), dapagliflozin was prescribed in combination with other AD therapy.
Patients starting on dapagliflozin differed in several demographic and health-related respects to patients starting another AD therapy during the same period. Dapagliflozin was predominantly used as a component of combination therapy, adding on to existing therapy. After initiation, switching to other AD treatments or adding to therapy was comparatively rare during the first year.
达格列净是一种人源钠-葡萄糖共转运蛋白 2（SGLT2）抑制剂，已被证明可改善 2 型糖尿病（T2DM）患者的血糖控制。本研究旨在评估与其他抗糖尿病（AD）药物相比，达格列净使用者的特征和治疗模式。
从 2012 年 11 月至 2014 年 4 月期间开始至少一种达格列净或其他 AD 治疗处方的 T2DM 患者的 IMS 德国疾病分析器数据库中收集数据。
达格列净联合治疗（n=1034；74%）的使用率高于单药治疗（n=371；26%）。与其他 AD 治疗使用者相比，达格列净使用者中 ⩽64 岁的比例更高（62.3% vs. 36.4%），男性比例更高（59.1% vs. 53.6%）。达格列净患者和其他 AD 治疗使用者的糖尿病平均病程相似（5.7 年 vs. 5.5 年），但达格列净使用者的 HbA1c 水平更高（8.2%（66mmol/mol）vs. 7.5%（58mmol/mol））。对于绝大多数（10mg 达格列净使用者的 71.5%和 5mg 使用者的 88.9%）患者，达格列净与其他 AD 治疗联合处方。
在同一时期开始使用达格列净的患者在几个人口统计学和健康相关方面与开始使用其他 AD 治疗的患者有所不同。达格列净主要作为联合治疗的一部分，添加到现有治疗中。起始后，在第一年期间，转换为其他 AD 治疗或添加到治疗中相对较少。
